Denmark rejects Sobi's blood disease medicine due to "unreasonably high" price
Aspaveli is too expensive and cannot be recommended as a standard treatment for Danish patients, says the Danish Medicines Council.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Danish patients will not be offered treatment with Aspaveli (pegcetacoplan), made by Swedish company Sobi, the Danish Medicines Council has decided according to media Hæmatologisk Tidsskrift, which covers news about blood diseases.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.